{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:17:23Z","timestamp":1770063443127,"version":"3.49.0"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":9697,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1980,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Twenty\u2010one children (19 with leukemia) were given 34 courses of vindesine on a weekly or twice\u2010weekly schedule in escalating doses. Thirty\u2010three courses were fully or partially evaluable for response and\/or toxicity. Granulocyto\u2010penia was the dose\u2010limiting toxicity. Transient jaw, neck, or bone pain was common after each dose. Motor weakness, paresthesias, and constipation were neither frequent nor severe. In this Phase I study, vindesine had some antileu\u2010kemia activity in children previously treated with vincristine and other drugs. Phase II studies are warranted and a starting dose of 1.85 mg\/m<jats:sup>2<\/jats:sup> twice weekly appears tolerable.<\/jats:p>","DOI":"10.1002\/mpo.2950080306","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T15:04:24Z","timestamp":1171983864000},"page":"243-250","source":"Crossref","is-referenced-by-count":5,"title":["Phase I evaluation of vindesine in children: A southwest oncology group pilot study"],"prefix":"10.1002","volume":"8","author":[{"given":"Diane","family":"Komp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tribhawan","family":"Vats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dell A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Vietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barth","family":"Hoogstraten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(77)80010-8"},{"key":"e_1_2_1_3_2","first-page":"2886","article-title":"Antitumor activity of deacetyl vinblastine amide sulfate (vindesine) in rodents and mitotic accumulation studies in culture","volume":"38","author":"Sweeney MJ","year":"1978","journal-title":"Cancer Res"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/15287397609529384"},{"key":"e_1_2_1_5_2","first-page":"128","article-title":"Initial clinical studies of vindesine (desacetyl vinblastine amide sulfate), abstracted","volume":"17","author":"Bodey GP","year":"1976","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_6_2","first-page":"1333","article-title":"Phase I trial of vindesine in patients with advanced cancer","volume":"62","author":"Currie V","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_7_2","first-page":"108","article-title":"Vindesine (V): Phase I study on a vinca alkaloid, abstracted","volume":"17","author":"Blum RH","year":"1976","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_8_2","first-page":"805","article-title":"Phase II clinical trial with vindesine for remission induction in acute leukemia blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: Absence of cross\u2010resistance with vincristine","volume":"62","author":"Mathe G","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_9_2","first-page":"1326","volume-title":"Current Chemotherapy","author":"Tan C","year":"1978"},{"key":"e_1_2_1_10_2","first-page":"1331","volume-title":"Current Chemotherapy","author":"Krivit W","year":"1978"},{"key":"e_1_2_1_11_2","first-page":"2603","article-title":"Pharmacokinetics of vindesine and vincristine in humans","volume":"37","author":"Owellen RJ","year":"1977","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","first-page":"129","article-title":"Initial clinical and pharmacological studies with vindesine: IV bolus versus 24 hour infusion, abstracted","volume":"19","author":"Ohnuma T","year":"1978","journal-title":"Proc Am Assoc Cancer Res"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950080306","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950080306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T03:11:44Z","timestamp":1699845104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950080306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980,1]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1980,1]]}},"alternative-id":["10.1002\/mpo.2950080306"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950080306","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1980,1]]}}}